Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cancer immunology, immunotherapy : CII

Showing results (1-10 of 6,490) with videos related to

Pageof 649
Sort By:
Cancer Immunology, Immunotherapy : CII|December 13, 2022
Porphyromonas gingivalis promotes the progression of oral squamous cell carcinoma by activating the neutrophil chemotaxis in the tumour microenvironmentZhi-Chen Guo, Si-Li Jing, Sakendeke Jumatai, et al.
Cancer Immunology, Immunotherapy : CII|May 6, 2022
Invariant NKT cell-augmented GM-CSF-secreting tumor vaccine is effective in advanced prostate cancer modelBindu Varghese, Lydia Lynch, Lianne E Vriend, et al.
Cancer Immunology, Immunotherapy : CII|May 7, 2022
Targeting tumor extracellular matrix activates the tumor-draining lymph nodesAlexander J Najibi, Ting-Yu Shih, David K Y Zhang, et al.
Cancer Immunology, Immunotherapy : CII|July 2, 2022
Long-term outcomes of patients with recurrent ovarian cancer treated with a polyvalent vaccine with bevacizumab combinationRyan M Kahn, Govind Ragupathi, Qin C Zhou, et al.
Cancer Immunology, Immunotherapy : CII|October 10, 2020
Sustained IL-2R signaling of limited duration by high-dose mIL-2/mCD25 fusion protein amplifies tumor-reactive CD8<sup>+</sup> T cells to enhance antitumor immunityRosmely Hernandez, Kevin H Toomer, Janika Põder, et al.
Cancer Immunology, Immunotherapy : CII|October 7, 2020
Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectivesJingjing Qu, Quanhui Mei, Lijun Chen, et al.
Cancer Immunology, Immunotherapy : CII|October 21, 2020
Notch signaling defects in NK cells in patients with cancerGulnur K Zakiryanova, Elena Kustova, Nataliya T Urazalieva, et al.
Cancer Immunology, Immunotherapy : CII|October 22, 2020
An immune-related gene signature for predicting survival and immunotherapy efficacy in hepatocellular carcinomaYifei Dai, Weijie Qiang, Kequan Lin, et al.
Cancer Immunology, Immunotherapy : CII|October 26, 2020
Merkel cell carcinoma in Latin America: a contribution from an expanded access program for avelumab to address issues from experts' recommendationsRodrigo Ramella Munhoz, Federico Cayol, Luis Corrales, et al.
Cancer Immunology, Immunotherapy : CII|March 29, 2020
In vivo anti-MUC1<sup>+</sup> tumor activity and sequences of high-affinity anti-MUC1-SEA antibodiesEdward Pichinuk, Michael Chalik, Itai Benhar, et al.
Pageof 649

Showing results (1-10 of 6,490) with videos related to

Sort By:
Pageof 649
Cancer Immunology, Immunotherapy : CII|December 13, 2022
Porphyromonas gingivalis promotes the progression of oral squamous cell carcinoma by activating the neutrophil chemotaxis in the tumour microenvironmentZhi-Chen Guo, Si-Li Jing, Sakendeke Jumatai, et al.
Cancer Immunology, Immunotherapy : CII|May 6, 2022
Invariant NKT cell-augmented GM-CSF-secreting tumor vaccine is effective in advanced prostate cancer modelBindu Varghese, Lydia Lynch, Lianne E Vriend, et al.
Cancer Immunology, Immunotherapy : CII|May 7, 2022
Targeting tumor extracellular matrix activates the tumor-draining lymph nodesAlexander J Najibi, Ting-Yu Shih, David K Y Zhang, et al.
Cancer Immunology, Immunotherapy : CII|July 2, 2022
Long-term outcomes of patients with recurrent ovarian cancer treated with a polyvalent vaccine with bevacizumab combinationRyan M Kahn, Govind Ragupathi, Qin C Zhou, et al.
Cancer Immunology, Immunotherapy : CII|October 10, 2020
Sustained IL-2R signaling of limited duration by high-dose mIL-2/mCD25 fusion protein amplifies tumor-reactive CD8<sup>+</sup> T cells to enhance antitumor immunityRosmely Hernandez, Kevin H Toomer, Janika Põder, et al.
Cancer Immunology, Immunotherapy : CII|October 7, 2020
Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectivesJingjing Qu, Quanhui Mei, Lijun Chen, et al.
Cancer Immunology, Immunotherapy : CII|October 21, 2020
Notch signaling defects in NK cells in patients with cancerGulnur K Zakiryanova, Elena Kustova, Nataliya T Urazalieva, et al.
Cancer Immunology, Immunotherapy : CII|October 22, 2020
An immune-related gene signature for predicting survival and immunotherapy efficacy in hepatocellular carcinomaYifei Dai, Weijie Qiang, Kequan Lin, et al.
Cancer Immunology, Immunotherapy : CII|October 26, 2020
Merkel cell carcinoma in Latin America: a contribution from an expanded access program for avelumab to address issues from experts' recommendationsRodrigo Ramella Munhoz, Federico Cayol, Luis Corrales, et al.
Cancer Immunology, Immunotherapy : CII|March 29, 2020
In vivo anti-MUC1<sup>+</sup> tumor activity and sequences of high-affinity anti-MUC1-SEA antibodiesEdward Pichinuk, Michael Chalik, Itai Benhar, et al.
Pageof 649